Compare LEE & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LEE | ACOG |
|---|---|---|
| Founded | 1890 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 115.5M |
| IPO Year | N/A | N/A |
| Metric | LEE | ACOG |
|---|---|---|
| Price | $3.63 | $5.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 36.2K | ★ 104.8K |
| Earning Date | 02-05-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $562,341,000.00 | $7,427,199.00 |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | N/A | $132.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.34 | $3.75 |
| 52 Week High | $15.16 | $11.54 |
| Indicator | LEE | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 55.95 |
| Support Level | $3.59 | $5.61 |
| Resistance Level | $4.51 | $6.20 |
| Average True Range (ATR) | 0.38 | 0.57 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 21.23 | 74.00 |
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.